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(57) ABSTRACT 
Provided are methods and compositions for the treatment or 
prevention of ocular angiogenesis and neovasculariZation. 
Administration of inhibitors of the CCR3 receptor or its 
ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 
(CCL26) inhibits ocular angiogenesis. 
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CCR3 INHIBITION FOR OCULAR 
ANGIOGENESIS AND MACULAR 
DEGENERATION 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application is a divisional of US. application Ser. No. 
12/247,722 ?led Oct. 8, 2008 Which claims priority to US. 
Application No. 60/998,348, ?led Oct. 9, 2007, the entire 
disclosures of Which are expressly incorporated by reference 
herein. 
FIELD OF THE INVENTION 
The present invention relates to the suppression of ocular 
angiogenesis by inhibiting the CCR3 receptor. 
DESCRIPTION OF THE RELATED ART 
The macula is the part of the retina Which is responsible for 
central vision. Age-related macular degeneration is a chronic 
eye disease that occurs When tissue in the macula deteriorates. 
Macular affects central vision, but not peripheral vision. 
Macular degeneration is the leading cause of severe vision 
loss in people age 60 and older. 
There are tWo forms of age-related macular degeneration: 
dry and Wet. Dry macular degeneration is the most common 
type of macular degeneration and occurs When cells of the 
macula sloWly begin to break doWn. YelloW deposits called 
“drusen” form under the retina betWeen the retinal pigmented 
epithelium (RPE) and Bruch’s membrane, Which supports the 
retina. The drusen deposits are debris associated With com 
promised cell metabolism in the RPE. Eventually there is a 
deterioration of the macular regions associated With the 
drusen deposits resulting in a loss of central vision. 
Wet macular degeneration occurs When abnormal bold ves 
sels groW behind the macula. These vessels are fragile and can 
leak ?uid and blood, Which result in scarring of the macula 
and raise the potential for rapid, severe damage. Bruch’s 
membrane breaks doWn, usually near drusen deposits. This is 
Where neW blood vessel groWth, or neovasculariZation, 
occurs. Central vision can become distorted or lost entirely in 
a shore period of time, sometimes Within days. Wet macular 
degeneration is responsible for about 10 percent of the cases 
of age-related macular degeneration, but it accounts for about 
90 percent of the cases of legal blindness. 
SUMMARY OF THE INVENTION 
In one aspect, the present invention relates to a method of 
inhibiting ocular angiogenesis. The method comprises expos 
ing a retinal or choroidal cell to a CCR3-inhibitory effective 
amount of a compound Which inhibits the activity of CCR3. 
The present invention also relates to a composition for the 
inhibition of ocular angiogenesis. The composition com 
prises a compound Which inhibits the activity of CCR3. 
In another aspect, the present invention relates to a method 
of diagnosing or monitoring choroidal neovasculariZation or 
Wet macular degeneration. The method comprises adminis 
tering a labeled CCR3-speci?c binding molecule to a patient 
and detecting the presence or absence of the labeled molecule 
in the retina or choroid of the patient, the presence of the 
labeled molecule being indicative of choroidal neovascular 
iZation or Wet macular degeneration. In still another aspect, 
the present invention relates to a method of treating choroidal 
neovasculariZation or Wet macular degeneration. The method 
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comprises administering an effective amount of a CCR3 
speci?c binding molecule to a patient having, or at risk for 
having, choroidal neovasculariZation or Wet macular degen 
eration. 
The invention also relates to a method for screening for a 
compound that interacts With CCR3. In one aspect, the 
method comprises contacting CCR3 polypeptide or binding 
fragment thereof With a test compound, and determining if a 
complex is formed betWeen CCR3 polypeptide or binding 
fragment thereof and the test compound. In another aspect, 
the test compound identi?ed as interacting With CCR3 is 
assayed for the ability to inhibit ocular angiogenesis. 
Other systems, methods, features and advantages of the 
present invention Will be or become apparent to one With skill 
in the art upon examination of the folloWing draWings and 
detailed description. It is intended that all such additional 
systems, methods, features and advantages be included 
Within this description, be Within the scope of the present 
invention, and be protected by the accompanying claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 illustrates the effect of laser injury on the number of 
CCR3 receptors on choroidal endothelial cells. 
FIG. 2 shoWs the effect of CCR3 antibody on the prolif 
eration of choroidal endothelial cells folloWing laser injury. 
FIG. 3 illustrates the dose-dependent effect of CCR3 anti 
body on choroidal neovasculariZation volume 
FIG. 4 shoWs lack of in?ltration of eosinophils and mast 
cells into the choroid folloWing laser injury. 
FIG. 5 illustrates the lack of change of number of in?ltrat 
ing macrophages in the choroid following laser injury and 
CCR3 antibody treatment. 
FIG. 6 shoWs the effect of laser injury on the number of 
CCR3 receptors in vivo on proliferating and quiescent mouse 
choroidal endothelial cells. 
FIG. 7 illustrates the dose-dependent reduction in CNV 
volume caused by the CCR3 small molecule antagonist 
SB328437 ((S)-methyl-2-naphthoylamino-3-(4-nitrophenyl) 
propionate. 
FIGS. 8(A), 8(B) and 8(C) present immunohistochemical 
analysis of the expression of CCR3 in the retina and choroid 
of normal patients and patients With age-related macular 
degeneration. 
FIG. 9 a graph of the CEC F-actin polymerization after 
eotaxin stimulation. PolymeriZation peaked at 10 seconds 
after stimulation With all eotaxins (eotaxin-1>eotaxin-3>eo 
taxin-2). Eotaxin-1 and -3 also induced a second delayed 
burst of F-actin polymeriZation betWeen 30 and 60 seconds. 
PBS controls resulted in no signi?cant increase in F-actin 
polymeriZation from baseline. 
FIG. 10A presents ?uorescent microscopic images seen 
from the ?uorescent baseplate assay. FIG. 10A shoWs the 
untreated baseline cultures. Minimal ?uorescence Was seen in 
the untreated baseline cultures Which Were approximately 
70-80% con?uent. 
FIG. 10B shoWs assay results With eotaxin 1. 
FIG. 10C shoWs assay results With eotaxin 2. 
FIG. 10D shoWs assay results With eotaxin 3. After 10 
seconds of eotaxin stimulation, hCEC cultures exhibited 
increased ?uorescence and cord formation characteristic of 
F-actin polymerization. Scale bars 50 um. 
FIG. 11 presents a Rac-1 activation assay. FIG. 11A shoWs 
that eotaxins activate Rac-1 GTPase in Human CECs 
(hCECs). hCECs) Were stimulated With Eotaxin- 1, 2 and 3 for 
the indicated times. Cells Without Eotaxin stimulation Were 
used as a control (0 sec). FIG. 11B shoWs a graph of the levels 
US 8,592,482 B2 
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of increase of active Rac-1, measured after normalizing 
against the control band density. Eotaxin-1 stimulation 
showed about 6.5 fold increase of Rac-1 activation at 10 
seconds (diamonds). Eotaxin-2 and Eotaxin-3 stimulation 
shoWed 3 to 5 fold increase of Rac-1 activation peaking at 60 
seconds (squares and triangles respectively). 
DETAILED DESCRIPTION 
Intraocular in?ammation is not clinically apparent in age 
related macular degeneration. HoWever, there is evidence 
suggesting an in?uential role for in?ammation in this condi 
tion. CCR3 is a promiscuous chemokine receptor that is pre 
dominantly expressed by eosinophils but also is found on 
other leukocytes and some endothelial and epithelial cells. 
The invention relates to methods and compositions for the 
treatment or prevention of ocular angiogenesis and neovas 
culariZation. Administration of inhibitors of the CCR3 recep 
tor or its ligands, for example eotaxin (CCL11), eotaxin-2 
(CCL24) or eotaxin-3 (CCL26), inhibits ocular angiogenesis. 
Ocular angiogenesis includes choroidal angiogenesis and 
retinal angiogenesis. Compositions and methods for inhibit 
ing CCR3, eotaxin (CCL11), eotaxin-2 (CCL24), and 
eotaxin-3 (CCL26) for the treatment and/or prevention of 
neovascular disease are provided. Also provided are novel 
therapeutic targets and diagnostic markers for choroidal 
neovasculariZation. 
Any compound Which inhibits the activity of CCR3 may be 
used in the present invention. Such compounds include 
inhibitory molecules Which bind directly to the CCR3 recep 
tor, antibodies Which bind the CCR3 receptor or to the natural 
ligands of the CCR3 receptor, including eotaxin (CCL11), 
eotaxin-2 (CCL24) and eotaxin-3 (CCL26), RNA, DNA or 
RNA/DNA aptamers Which speci?cally bind CCR3, eotaxin, 
eotaxin-2 or eotaxin-3, and siRNA or anti-sense oligonucle 
otides Which inhibit the expression of CCR3, eotaxin, 
eotaxin-2 or eotaxin-3. Additional compounds Which inhibit 
the activity of CCR3 include inhibitory molecules Which 
speci?cally bind CCR3, eotaxin, eotaxin-2 or eotaxin-3, 
including an oligopeptide, small molecule antagonist (e.g., 
organic molecule having a molecular Weight less than 2000, 
or less than 1000, or less than 500), riboZyme, intrabody or 
intraceptor. An intrabody refers to an antibody produced 
intracellularly, for example, a single chain antibody (such as 
a single chain Fv antibody fragment) expressed inside a cell 
transformed With an appropriate exogenous nucleic acid. An 
intraceptor refers to an receptor (such as a receptor for CCR3, 
eotaxin, eotaxin-2 or eotaxin-3) produced intracellularly, for 
example, a CCR3, eotaxin, eotaxin-2 or eotaxin-3 receptor 
expressed inside a cell transformed With an appropriate exog 
enous nucleic acid. 
Numerous “small molecule” inhibitors for the CCR3 
receptor have been developed and can be used in the present 
invention. In one aspect the CCR3 inhibitor is an organic 
molecule having a molecular Weight less than 2000. In 
another aspect of the invention, the CCR3 inhibitor is an 
organic molecule having a molecular Weight less than 1000. 
In yet another aspect of the invention, the CCR3 inhibitor is 
an organic molecule having a molecular Weight less than 500. 
The CCR3 receptor inhibitors include piperidine derivatives, 
piperidine amides and biperidine compounds such as those 
described in U.S. Pat. Nos. 6,984,651 and 6,903,115, and 
U.S. published applications 20050176708, 20050182094 and 
20050182095; heterocyclic piperidines such as those 
described in U.S. Pat. No. 6,759,411; diphenyl-piperidine 
derivatives such as those described in U.S. Pat. No. 6,566, 
376; 2,5-substituted pyrimidine derivatives such as those 
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described in U.S. Pat. No. 6,984,643; piperiZinones such as 
those described in U.S. Pat. No. 6,974,869; bicycylic and 
tricyclic amines such as those described in U.S. Pat. No. 
6,960,666; N-ureidoalkyl-piperidines such as those 
described in U.S. Pat. Nos. 6,949,546, 6,919,368, 6,906,066, 
6,897,234, 6,875,776, 6,780,857, 6,627,629, 6,521,592 and 
6,331,541; bicyclic diamines such as those described in U.S. 
Pat. No. 6,821,964; benZylcycloalkyl amines such as those 
described in U.S. Pat. No. 6,864,380; 2-substituted-4-nitro 
gen heterocycles such as those described in U.S. Pat. No. 
6,706,735; ureido derivatives of poly-4-amino-2-carboxy-1 
methyl pyrrole compounds; bicyclic and bridged nitrogen 
heterocycles such as those described in U.S. published appli 
cation 20050234034; aZetidine derivatives such as those 
described in U.S. published application 20050222118; sub 
stituted fused bicyclic amines such as those described in U.S. 
published application 20050197373; substituted spiro aZabi 
cyclics such as those described in U.S. published application 
20050197325; piperidine-substituted indoles or hetero 
derivatives thereof such as those described in U.S. published 
application 20050153979; piperidinyl and piperaZinyl com 
pounds substituted With bicyclo-heterocyclylalkyl groups 
such as those described in U.S. published application 
20050090504; arylsulfonamide derivatives such as those 
described in U.S. published application 20050070582; 
1-phenyl-1,2-diaminoethane derivatives such as those 
described in U.S. published application 20040063779; (N-{ 
[2S]-4-(3,4-dichlorobenZyl)morpholin-2-yl}methyl)-N'[(2 
methyl-2H-tetraaZol-5-yl)methyl]urea) (see, e. g., Nakamura 
et al., Immunol Res., 33:213-222, 2006; N-{(3R)-1-[(6 
?uoro-2-naphthyl)methyl]pyrrolidin-3 -yl} -2-{ 1 -[(3 -me 
thyl-1-oxidopyridin-2-yl)carbonyl]piperidin-4 
ylidene}acetamide (see, e.g., Suzuki et al., Biochem. 
Biophys. Res. Commun., 339:1217-1223, 2006; N-{(3R)-1 
[(6-?uoro-2-naphthyl)methyl]pyrrolidin-3 -yl}-2-{1-[(5 -hy 
droxy-3-methylpyridin-2-yl)carbonyl]piperidin-4 
ylidene}acetamide hemifumarate (see, e.g., Morokata et al., 
J. Pharmacol. Exp. Ther., Dec. 9, 2005 [Epub ahead of print]); 
bipiperidine amide antagonists of CCR3 such as those 
described in Ting et al., Bioorg. Med. Chem. Lett., 15:3020 
3023 -2005; (S) -methyl-2-naphthoylamino -3 -(4-nitrophenyl) 
propionate (see, e.g., Beasley et al., J. Allergy Clin. Immu 
nol., 105: S466-S472, 2000; and the CCR3 antagonist 
compounds described in Fryer et al., J. Clin. Invest., 116:228 
236, 2006. 
Additional compounds for inhibiting the CCR3 receptor 
include RNA, DNA or RNA/DNA aptamers directed against 
CCR3, eotaxin, eotaxin-2 or eotaxin-3. Exemplary methods 
for making aptamers are described in U.S. Pat. Nos. 5,270, 
163, 5,840,867, 6,180,348 and 6,699,843. 
Additional compounds for inhibiting the CCR3 receptor 
include anti-sense oligonucleotides or siRNAs directed 
against CCR3, eotaxin, eotaxin-2 or eotaxin-3, including the 
anti-sense oligonucleotides directed against the CCR3 recep 
tor such as that described in U.S. Pat. No. 6,822,087. 
The siRNAs for use in the present invention are designed 
according to standard methods in the ?eld of RNA interfer 
ence. Introduction of siRNAs into cells may be by transfec 
tion With expression vectors, by transfection With synthetic 
dsRNA, or by any other appropriate method. Transfection 
With expression vectors is preferred. 
The expression vectors Which can be used to deliver siRNA 
according to the invention include retroviral, adenoviral and 
lentiviral vectors. The expression vector includes a sequence 
Which codes for a portion of the target gene (e.g., CCR3 
receptor, eotaxin, eotaxin-2 or eotaxin-3) Which is to be 
silenced. The target gene sequence is designed such that, 
US 8,592,482 B2 
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upon transcription in the transfected host, the target RNA 
sequence forms a hairpin structure due to the presence of 
self-complementary bases. Processing Within the cell 
removes the loop resulting in formation of a siRNA duplex. 
The double stranded RNA sequence should be less than 30 
nucleotide bases; preferably the dsRNA sequence is 19-25 
bases in length; more preferably the dsRNA sequence is 20 
nucleotides in length. 
The expression vectors may include one or more promoter 
regions to enhance synthesis of the target gene sequence. 
Promoters Which can be used include CMV promoter, SV40 
promoter, promoter of mouse U6 gene, and promoter of 
human H1 gene. 
One or more selection markers may be included to facili 
tate transfection With the expression vector. The selection 
marker may be included Within the expression vector, or may 
be introduced on a separate genetic element. For example, the 
bacterial hygromycin B phosphotransferase gene may be 
used as a selection marker, With cells being groWn in the 
presence of hygromycin to select for those cells transfected 
With the aforementioned gene. 
Synthetic dsRNA may also be introduced into cells to 
provide gene silencing by siRNA. The synthetic dsRNAs are 
less than 30 base pairs in length. Preferably the synthetic 
dsRNAs are 19-25 base pairs in length. More preferably the 
dsRNAs are 19, 20 or 21 base pairs in length, optionally With 
2-nucleotide 3' overhangs. The 3' overhangs are preferably 
TT residues. 
Synthetic dsRNAs can be introduced into cells by injec 
tion, by complexing With agents such as cationic lipids, by use 
of a gene gun, or by any other appropriate method. 
Additional compounds for inhibiting the CCR3 receptor 
include antibodies Which speci?cally bind the CCR3 recep 
tor, eotaxin, eotaxin-2 or eotaxin-3. Exemplary antibodies 
Which speci?cally bind and inhibit the CCR3 receptor are 
described in US. Pat. Nos. 6,806,061 and 6,207,155, and in 
US. published applications 20050191702, 20050069955, 
and 20020147312. Exemplary antibodies Which speci?cally 
bind and inhibit eotaxin and eotaxin-2 are described in US. 
Pat. Nos. 6,946,546 and 6,635,251, and in US. published 
applications 20040191255 and 20040014132. 
The antibodies of the present invention can be polyclonal 
or monoclonal, and the term antibody is intended to encom 
pass both polyclonal and monoclonal antibodies. Antibodies 
of the present invention can be raised against an appropriate 
immunogen, including proteins or polypeptides of the present 
invention, such as isolated and/or recombinant mammalian 
CCR3 receptor, eotaxin, eotaxin-2 or eotaxin-3 protein or 
portion thereof, or synthetic molecules, such as synthetic 
peptides. 
Preparation of immunizing antigen, and polyclonal and 
monoclonal antibody production can be performed using any 
suitable technique. A variety of methods have been described 
(see e.g., Kohler et al., Nature, 256: 495-497 (1975) and Eur. 
J. Immunol. 6: 511-519 (1976); Milstein et al., Nature 266: 
550-552 (1977); KoproWski et al., US. Pat. No. 4,172,124; 
HarloW, E. and D. Lane, 1988, Antibodies: A Laboratory 
Manual, (Cold Spring Harbor Laboratory: Cold Spring Har 
bor, N.Y.); Current Protocols In Molecular Biology, Vol. 2 
(Supplement 27, Summer ’94), Ausubel, F. M. et al., Eds., 
(John Wiley & Sons: NeW York, NY), Chapter 11, (1991)). 
Generally, a hybridoma is produced by fusing a suitable 
immortal cell line (e.g., a myeloma cell line such as SP2/0) 
With antibody producing cells. The antibody producing cell, 
preferably those of the spleen or lymph nodes, are obtained 
from animals immunized With the antigen of interest. The 
fused cells (hybridomas) are isolated using selective culture 
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conditions, and cloned by limiting dilution. Cells Which pro 
duce antibodies With the desired speci?city are selected by a 
suitable assay (e.g., ELISA). 
Single chain antibodies, and chimeric, humanized or, pri 
matized (CDR-grafted) antibodies, as Well as chimeric or 
CDR-grafted single chain antibodies, comprising portions 
derived from different species, are also encompassed by the 
present invention and the term “antibody”. The various por 
tions of these antibodies can be joined together chemically by 
conventional techniques, or can be prepared as a contiguous 
protein using genetic engineering techniques. For example, 
nucleic acids encoding a chimeric or humanized chain can be 
expressed to produce a contiguous protein. See, e.g., Cabilly 
et al., US. Pat. No. 4,816,567; Cabilly et al., European Patent 
No. 0,125,023. B1; Boss et al., US. Pat. No. 4,816,397; Boss 
et al., European Patent No. 0,120,694 B1; Neuberger, M. S. et 
al., WO 86/01533; Neuberger, M. S. et al., European Patent 
No. 0,194,276 B1; Winter, US. Pat. No. 5,225,539; and Win 
ter, European Patent No. 0,239,400 B1. See also, NeWman, R. 
et al., BioTechnology, 10: 1455-1460 (1992), regarding pri 
matized antibody, and Ladner et al., US. Pat. No. 4,946,778 
and Bird, R. E. et al., Science, 242: 423-426 (1 988)) regarding 
single chain antibodies. 
In addition, functional fragments of antibodies, including 
fragments of chimeric, humanized, primatized or single chain 
antibodies, can also be produced. Functional fragments of 
foregoing antibodies retain at least one binding function and/ 
or modulation function of the full-length antibody from 
Which they are derived. For example, antibody fragments 
capable of binding to a mammalian CCR3 receptor, eotaxin, 
eotaxin-2 or eotaxin-3 or portion thereof, including, but not 
limited to, Fv, Fab, Fab' and F(ab').sub.2 fragments are 
encompassed by the invention. Such fragments can be pro 
duced by enzymatic cleavage or by recombinant techniques. 
For instance, papain or pepsin cleavage can generate Fab or 
F(ab').sub.2 fragments, respectively. Alternatively, antibodies 
can be produced in a variety of truncated forms using anti 
body genes in Which one or more stop codons has been 
introduced upstream of the natural stop site. For example, a 
chimeric gene encoding a F(ab').sub.2 heavy chain portion 
can be designed to include DNA sequences encoding the 
CH.sub.1 domain and hinge region of the heavy chain. 
The antibodies of the present invention can be used to 
modulate receptor or ligand function in research and thera 
peutic applications. For instance, antibodies can act as inhibi 
tors to inhibit (reduce or prevent) (a) binding (e.g., of a ligand, 
a second inhibitor or a promoter) to the receptor, (b) a receptor 
signalling, (c) and/or a stimulatory function. Antibodies 
Which act as inhibitors of receptor function can block ligand 
or promoter binding directly or indirectly (e.g., by causing a 
conformational change). For example, antibodies can inhibit 
receptor function by inhibiting binding of a ligand, or by 
desensitization (With or Without inhibition of binding of a 
ligand). 
Anti-idiotypic antibodies. are also provided. Anti-idio 
typic antibodies recognize antigenic determinants associated 
With the antigen-binding site of another antibody. Anti-idio 
typic antibodies can be prepared against a second antibody by 
immunizing an animal of the same species, and preferably of 
the same strain, as the animal used to produce the second 
antibody. See e.g., US. Pat. No. 4,699,880. Single chain, and 
chimeric, humanized or primatized (CDR-grafted), as Well as 
chimeric or CDR-grafted single chain anti-idiotypic antibod 
ies can be prepared, and are encompassed by the term anti 
idiotypic antibody. Antibody fragments of such antibodies 
can also be prepared. 
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Modulation of mammalian CCR3 receptor function 
according to the present invention, through the inhibition of at 
least one function characteristic of a mammalian CCR3 
receptor, provides an effective and selective Way of inhibiting 
ocular angiogenesis. One or more inhibitors of CCR3 recep 
tor function, such as those identi?ed as described herein, can 
be used to inhibit ocular angiogenesis for therapeutic pur 
poses. 
Thus, the present invention provides a method of inhibiting 
ocular angiogenesis in an individual in need of such therapy, 
comprising administering a compound Which inhibits mam 
malian CCR3 receptor function to an individual in need of 
such therapy. Such individuals include those having age 
related macular degeneration. 
The present inventors have found that CCR3 is highly 
expressed by endothelial cells of choroidal neovasculariZa 
tion membrane in patients With Wet age-related macular 
degeneration. Thus, in one aspect of the invention, CCR3 
expression is used as a target for diagnosis or therapy of 
choroidal neovasculariZation or Wet age-related macular 
degeneration. For diagnosis of choroidal neovasculariZation 
or Wet macular degeneration, a molecule Which can speci? 
cally bind CCR3 or any portion thereof (e.g., an antibody) is 
administered to the patient. A reporter group is attached to the 
CCR3-speci?c binding molecule so that in situ expression of 
CCR3 can be monitored. Appropriate reporter groups include 
?uorescent dyes, radionuclides, and dense metal particles, 
although any appropriate detectable reporter group can be 
used. An abundance of CCR3-speci?c binding molecule 
detected in the retina or choroid Would be indicative of cho 
roidal neovascularization or Wet macular degeneration. Early 
detection of CCR3 overexpression in the retina or choroid 
before overt signs of macular degeneration develop alloWs for 
therapy to be initiated early, even before choroidal neovascu 
lariZation takes place, thereby leading to more effective treat 
ment of the disease. In addition, administration of the labeled 
CCR3-speci?c binding molecule can be used to monitor the 
progress of any therapy. 
Administration of CCR3-speci?c binding molecule can 
also be used as a Way of treating choroidal neovasculariZation 
or Wet macular degeneration. The CCR3-speci?c binding 
molecule can act directly by removing CCR3, thereby stop 
ping or reducing neovasculariZation. In another aspect, the 
CCR3-speci?c binding molecule can have attached to it a 
toxin, radionuclide or other entity Which kills or inhibits the 
cells involved in neovasculariZation. Alternatively, a CCR3 
speci?c binding molecule can be administered to the patient 
in conjunction With, or folloWed by, administration of a sec 
ond molecule Which speci?cally binds the CCR3-speci?c 
binding molecule. A toxin, radionuclide or other entity Which 
kills or inhibits the cells involved in neovasculariZation is 
attached to the second molecule, thereby providing for treat 
ment of choroidal neovasculariZation or Wet macular degen 
eration. 
The methods of the present invention can be used in any 
mammalian species, including human, monkey, coW, sheep, 
pig, goat, horse, mouse, rat, dog, cat, rabbit, guinea pig, 
hamster and horse. Humans are preferred. 
According to the method of the invention, one or more 
compounds can be administered to the host by an appropriate 
route, either alone or in combination With another drug. An 
effective amount of a compound (e.g., a small molecule 
CCR3 receptor antagonist Which inhibits ligand binding, an 
antibody or an siRNA) is administered. An effective amount 
is an amount su?icient to achieve the desired therapeutic 
effect, under the conditions of administration, such as an 
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amount su?icient for inhibition of a CCR3 receptor function, 
and thereby inhibition of ocular angiogenesis. 
A variety of routes of administration are possible includ 
ing, but not necessarily limited to oral, dietary, topical (e.g., 
eye drops), parenteral (e.g., intravenous, intraarterial, intra 
muscular, subcutaneous injection), inhalation (e.g., intra 
bronchial, intranasal or oral inhalation, intranasal drops), and 
intraocular injection routes of administration, depending on 
the disease or condition to be treated. Intraocular injection 
routes include periocular (subconjunctival/transscleral), 
intravitreous, subretinal, suprachoroidal and intracameral 
modes of injection. 
Formulation of a compound to be administered Will vary 
according to the route of administration selected (e.g., solu 
tion, emulsion, capsule). An appropriate composition com 
prising the compound to be administered can be prepared in a 
physiologically acceptable vehicle or carrier. For solutions or 
emulsions, suitable carriers include, for example, aqueous or 
alcoholic/ aqueous solutions, emulsions or suspensions, 
including saline and buffered media. Parenteral vehicles can 
include sodium chloride solution, Ringer’s dextrose, dextrose 
and sodium chloride, lactated Ringer’s or ?xed oils. Intrave 
nous vehicles can include various additives, preservatives, or 
?uid, nutrient or electrolyte replenishers (See, generally, 
Remington’s Pharmaceutical Science, 16th Edition, Mack, 
Ed. 1980). For inhalation, the compound is solubiliZed and 
loaded into a suitable dispenser for administration (e.g., an 
atomiZer, nebuliZer or pressuriZed aerosol dispenser). As 
another example, a compound may be administered via a 
sustained release device or composition Which is implanted in 
the vitreous humor, aqueous humor, on the sclera, in the 
sclera, in the suprachoroidal space, or in the subretinal space. 
In another embodiment, the present invention provides 
methods for screening compounds that interact With CCR3. 
The present invention is useful for screening compounds by 
using CCR3 polypeptide or binding fragments thereof in any 
of a variety of drug screening techniques. The CCR3 polypep 
tide or fragment employed in such a test may either be free in 
solution, a?ixed to a solid support, borne on a cell surface or 
located intracellularly. One method of drug screening utiliZes 
eukaryotic or prokaryotic host cells Which are stably trans 
formed With recombinant nucleic acids expressing the 
polypeptide or fragment. Drugs are screened against such 
transformed cells in competitive binding assays. Such cells, 
either in viable or ?xed form, can be used for standard binding 
assays. One may measure, for example, the formation of 
complexes betWeen CCR3 and the agent being tested. Alter 
natively, one can examine the diminution in complex forma 
tion betWeen CCR3 and its target cell, monocyte, etc. caused 
by the agent being tested. 
Thus, the present invention provides methods of screening 
for drugs or any other agents Which can affect ocular angio 
genesis and disease. These methods comprise contacting such 
an agent With a CCR3 polypeptide or fragment thereof and 
assaying (i) for the presence of a complex betWeen the agent 
and the CCR3 polypeptide or fragment, or (ii) for the pres 
ence of a complex betWeen the CCR3 polypeptide or frag 
ment and the cell, by methods Well knoWn in the art. In such 
competitive binding assays, the CCR3 polypeptide or frag 
ment is typically labeled. After suitable incubation, free 
CCR3 polypeptide or fragment is separated from that present 
in bound form, and the amount of free or uncomplexed label 
is a measure of the ability of the particular agent to bind to 
CCR3 or to interfere With the CCR3 and agent complex. 
Another technique for drug screening provides high 
throughput screening for compounds having suitable binding 
a?inity to the CCR3 polypeptide and is described in detail in 
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European PatentApplication 84/ 03564, published on Sep. 13, 
1984, incorporated herein by reference. Brie?y stated, large 
numbers of different small peptide test compounds are syn 
thesiZed on a solid substrate, such as plastic pins or some 
other surface. The peptide test compounds are reacted With 
CCR3 polypeptide and Washed. Bound CCR3 polypeptide is 
then detected by methods Well knoWn in the art. Puri?ed 
CCR3 can also be coated directly onto plates for use in the 
aforementioned drug screening techniques. In addition, non 
neutraliZing antibodies can be used to capture the peptide and 
immobiliZe it on the solid support. 
This invention also contemplates the use of competitive 
drug screening assays in Which neutraliZing antibodies 
capable of binding CCR3 speci?cally compete With a test 
compound for binding to CCR3 polypeptides or fragments 
thereof In this manner, the antibodies can be used to detect the 
presence of any peptide Which shares one or more antigenic 
determinants With CCR3. 
The present invention also contemplates the use of drug 
screening assays in Which drugs or any other agents are moni 
tored in a bioassay, such as the ability of the drug or agent to 
inhibit ocular angiogenesis. Such a drug screening assay may 
be used in conjunction With the various binding assays 
described above, i.e., drugs or other agents may be ?rst tested 
for their ability to bind to CCR3, and those compounds hav 
ing binding af?nity for CCR3 are then tested in a bioassay, 
such as the ability of the drug or agent to inhibit ocular 
angiogenesis. Alternatively, the bioassay may be conducted 
With the drug or agent With or Without a compound Which 
blocks the action of CCR3, such as an antibody against 
CCR3. Inhibition of ocular angiogenesis With the drug or 
agent but no inhibition of ocular angiogenesis With drug or 
agent in the presence of a compound Which blocks the action 
of CCR3 Would be indicative of a compound that inhibits 
ocular angiogenesis by interacting With CCR3. Similar 
screening assays can be performed comparing ocular angio 
genesis in Wild-type cells versus cells in Which the genes for 
CCR3 are knocked out, With inhibition of ocular angio genesis 
in Wild-type cells due to exposure to drug agent and no inhi 
bition in the knockout cells being indicative of the drug or 
agent inhibiting ocular angiogenesis by interacting With 
CCR3. 
Example 1 
Methods 
Laser photocoagulation (532 nm, 200 mW, 100 ms, 75 um) 
(OcuLight GL, lridex Corporation) Was performed (volume 
studies: 3/eye; protein analyses/?ow cytometry: 12/eye) on 
both eyes of each animal to induce CNV (choroidal neovas 
culariZation). CNV volumes Were measured by scanning 
laser confocal microscope (TCS SP, Leica) With 0.5% FITC 
Grz?‘onia simplicifolia lsolectin B4 (Vector Laboratories). 
CNV Was induced by laser injury in C57BL/6] and Ccr3_/_ 
mice and volumes measured 7 days later by confocal evalu 
ation of Grifonia simplicifolia lsolectin B4 staining of RPE 
choroid ?atmounts. Neutralizing antibodies (Ab) against 
CCR3, eotaxin (CCL-11), eotaxin-2 (CCL-24), RANTES, 
MCP-3 or control goat IgG or rat lgG2a Were injected into the 
vitreous humor folloWing injury. 
FloW cytometry Was used to determine the numbers of 
eosinophils, mast cells and macrophages in the choroid, 
expression of CCR3 by various cell types in the eye, and the 
cell cycle state of choroidal endothelial cells (CECs) in vivo. 
Suspensions of cells isolated from mouse RPE/choroid by 
incubation With collagenase D (20 U/ml; Roche Diagnostics) 
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treatment Were incubated in Fc block (0.5 mg/ml; BD Pharm 
ingen) for 15 min on ice. Rat antibody to mouse CCR3 
(1:250; Santa CruZ) coupled With PE-donkey antibody to rat 
lgG (1:250; Jackson lmmunoresearch) Were used to quantify 
cell surface receptor expression on choroidal endothelial 
cells, de?ned by CD31"VEGFR-2+ expression, gated by 
FlTC-conjugated rat antibody to mouse CD31 (1:250; BD 
Biosciences) and PerCP-Cy5.5-conjugated rat antibody to 
mouse CD11b (1:50; BDBiosciences). Macrophages, neutro 
phils, eosinophils and mast cells Were de?ned as 134/80+ 
CD11c‘, Gr-1+F4/80_, CCR3’"CD3‘CD117””CD49d+ and 
CCR3i”’CD3_CD117hiCD49d+ cells, respectively. DNA 
content for cell cycle Was analyZed after incubation With 
propidium iodide (0.05 mg/ml; Molecular Probes) containing 
0.1% Triton X-100 and RNase A (0.1 mg/ml; Roche). 
Because the probability of each laser lesion developing 
CNV is in?uenced by the group to Which it belongs, the 
mouse, the eye, and the laser spot, the mean lesion volumes 
Were compared using a linear mixed model With a split plot 
repeated measures design. The Whole plot factor Was the 
genetic group to Which the animal belonged While the split 
plot factor Was the eye. Statistical signi?cance Was deter 
mined at the 0.05 level. Post hoc comparison of means Was 
constructed With a Bonferroni adjustment for multiple com 
parisons. 
Results 
As illustrated by FIG. 1, the number of CCR3 receptors on 
choroidal endothelial cells in vivo folloWing laser injury (red) 
is signi?cantly greater than the number before injury (green), 
indicating upregulation of CCR3 receptors on these cells. 
Eosinophils or mast cells are the principal cells in most sys 
tems that respond to CCR3. HoWever, the number of eosino 
phils and mast cells in the choroid Was unaffected by injury or 
CCR3 Ab (FIG. 4). CCR3 Ab did not inhibit choroidal mac 
rophage in?ltration folloWing injury (FIG. 5), indicating that 
laser injury is not Working by anti-in?ammatory means. As 
illustrated by FIG. 3, CCR3 Ab suppressed CNV volume in 
C57BL/6] mice by nearly 60% in a dose-dependent and sta 
tistically signi?cant manner compared to vehicle control 
(PBS) and control antibody (rat lgG2a). FIG. 2 demonstrates 
that CCR3 Ab blockade, but not control antibody (rat lgG2a), 
inhibited proliferation (S phase) of CECs (choroidal endot 
helial cells) in vivo folloWing laser injury. Experiments in 
Ccr3 —/— mice con?rmed these results. Of the CCR3 ligands, 
blockade of only eotaxin (45%) or eotaxin-2 (70%) sup 
pressed CNV in C57BL/6] mice compared to control anti 
bodies (all Ps<0.001). Experiments in Cc111—/— and 
Cc124—/— mice con?rmed these results. 
These ?ndings demonstrate that CCR3 receptor promotes 
angiogenesis not via leukocyte modulation but rather by 
direct effects on CECs. Thus, CCL-11, CCL-24, and CCR3 
are neW targets for neovascular AMD (age-related macular 
degeneration). 
Example 2 
Methods 
Male C57BL/6J mice (Jackson Laboratories) betWeen 6 
and 8 Weeks of age Were used to minimiZe variability. For all 
procedures, anesthesia Was achieved by intraperitoneal inj ec 
tion of 50 mg/kg ketamine hydrochloride (Ft. Dodge Animal 
Health) and 10 mg/kg xylaZine (Phoenix Scienti?c), and 
pupils Were dilated With topical 1% tropicamide (Alcon 
Laboratories). 
Laser photocoagulation (532 nm, 200 mW, 100 ms, 75 um) 
(OcuLight GL, lridex Corporation) Was performed (volume 
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studies: 3/eye; protein analyses/?oW cytometry: 12/eye) on 
both eyes of each animal to induce CNV. CNV volumes Were 
measured by scanning laser confocal microscope (TCS SP, 
Leica) With 0.5% FlTC-Grz?bnia simplicifolia lsolectin B4 
(Vector Laboratories) or 0.5% FlTC-rat antibody against 
mouse CD31 (BD Biosciences). Volumes obtained by lectin 
and CD31 staining Were highly correlated (r2:0.95). (S) 
Methyl-2-naphthoylamino-3-(4-nitrophenyl)propionate 
(SB328437; Calbiochem) dissolved in DMSO Was injected 
into the vitreous humor of Wild-type mice using a 33-gauge 
double-caliber needle (Ito Corporation) immediately after 
laser injury. 
Suspensions of cells isolated from mouse RPE/choroid by 
incubation With collagenase D (20 U/ml; Roche Diagnostics) 
treatment Were incubated in Fc block (0.5 mg/ml; BD Pharm 
ingen) for 15 min on ice. Rat antibody to mouse CCR3 
(1:250; Santa Cruz) coupled With PE-donkey antibody to rat 
lgG (1:250; Jackson lmmunoresearch) Were used to quantify 
cell surface receptor expression on choroidal endothelial 
cells, de?ned by CD31"VEGFR-2+ expression. DNA content 
for cell cycle Was analyzed after incubation With propidium 
iodide (0.05 mg/ml; Molecular Probes) containing 0.1% Tri 
ton X-100 and RNase A (0.1 mg/ml; Roche). Paraf?n embed 
ded sections of human eyes or CNV membranes Were stained 
With antibodies against human CCR3 or human vWF and 
identi?ed With Cy2 or Cy3 secondary antibodies. 
Results 
As illustrated by FIG. 6, folloWing laser injury there is a 
signi?cantly greater number of CCR3 receptors in vivo on 
proliferating mouse choroidal endothelial cells (S+G2/M cell 
cycle phase; light curve) than the number on quiescent cells 
(G0/ G1 phases; dark curve). The results indicate that there is 
upregulation of CCR3 receptors on the proliferating cells. 
FIG. 7 shoWs that the CCR3 small molecule antagonist 
SB328437 ((S)-methyl-2-naphthoylamino-3-(4-nitrophenyl) 
propionate) reduces CNV volume in a dose-dependent and 
statistically signi?cant manner compared to vehicle control 
(DMSO). In FIG. 8(A), immunohistochemistry shoWs that 
CCR3 is expressed in the neural retina of patients Without 
age-related macular degeneration (AMD) but not in the chor 
oid. In FIG. 8(B), CCR3 expression is reduced in the retina 
and absent in the choroid of patients With AMD Who have 
drusen but not choroidal neovascularization (CNV). FIG. 
8(C) shoWs that CCR3 is highly expressed in the endothelial 
cells of a CNV membrane excised from a patient With AMD, 
both on endothelial cells and in the stroma. 
Example 3 
A F-actin polymerization assay Was performed. 10,000 
cells from early passage primary hCEC isolates (n:3) Were 
seeded in black-Walled 96-Well plates and groWn to 70-80% 
con?uency in fully supplemented EGM-2MV. Cultures Were 
serum starved overnight in basal media and then stimulated 
With recombinant human eotaxin-1 (10 ng/mL), eotaxin-2 
(100 ng/mL), eotaxin-3 (2 ug/mL) (Peprotech), or vehicle 
control (PBS). At 0, 10, 30, 60, or 120 second time-points 
(n:4 per group), cells Were ?xed in 3.7% paraformaldehyde 
for 10 minutes, Washed, permeabilized in PBS With 0.1% 
Triton-X, and then stained With rhodamine labeled Phalloidin 
(1:200, lnvitrogen) per manufacturer’s recommendations. 
Plates Were analyzed on a ?uorescent plate reader (Synergy 4, 
Biotek) folloWed by ?uorescent microscopy (Nikon E800). 
F-actin polymer ratios betWeen baseline and treated cul 
tures Were calculated using a ?uorescent based plate assay. As 
seen in FIG. 9, polymerization peaked at 10 seconds after 
stimulation With all eotaxins (eotaxin-1>eotaxin-3>eotaxin 
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2). Eotaxin-1 and -3 also induced a second delayed burst of 
F-actin polymerization betWeen 30 and 60 seconds. PBS 
controls resulted in no signi?cant increase in F-actin poly 
merization from baseline. 
As shoWn in FIG. 10, ?uorescent microscopic images 
shoWed minimal ?uorescence in untreated baseline cultures 
that Were approximately 70-80% con?uent. After 10 seconds 
of eotaxin stimulation, hCEC cultures exhibited increased 
?uorescence and cord characteristic of F-actin polymeriza 
tion. 
Example 4 
A Rac-1 activation assay Was performed. Human CECs 
Were cultured in EGM-2 MV containing 5% FBS. Prior to 
starting the assay, cells Were serum starved With basal 
medium (MCDB131) supplemented With 1% FBS overnight. 
Cells Were stimulated for designated times With Eotaxin-1, 2 
and 3 (10 ng/ml, 100 ng/ml and 2 ug/ml respectively). Equal 
amounts of lysates (500 pg) Were incubated With GST-Pakl - 
PBD agarose beads (Upstate) to pull-doWn active GTP-bound 
Rac-1 at 40 C. for 1 hour With rotation. The samples Were 
subsequently analyzed for bound Rac-1 by Western blot 
analysis using an anti-Rac-1 antibody (Upstate). Band den 
sity Was measured using VisionWorksLS softWare (UV P). 
hCECs) Were stimulated With Eotaxin-1, 2 and 3 for indi 
cated times. Cells Without Eotaxin stimulation Were used as a 
control (0 sec). Equal amount (500 pg) of total cell lysates Was 
used to determine the GTP-bound Rac-1 (active) by pull 
doWn assays. Levels of increase of active Rac-1 Were mea 
sured after normalizing against the control band density. As 
shoWn in FIG. 11B, eotaxins activated Rac-1 GTPase in 
Human CECs (hCECs). Eotaxin-1 stimulation shoWed about 
6.5 fold increase of Rac-1 activation at 10 seconds. Eotaxin-2 
and Eotaxin-3 stimulation shoWed 3 to 5 fold increase of 
Rac-1 activation peaking at 60 seconds. 
All references cited in this disclosure are incorporated by 
reference to the same extent as if each reference had been 
incorporated by reference in its entirety individually. 
While the invention has been described in detail and With 
reference to speci?c embodiments thereof, it Will be apparent 
to one skilled in the art that various variations and modi?ca 
tions can be made therein Without departing from the sprit and 
scope thereof. All such variations and modi?cations are 
intended to be includedWithin the scope of this disclosure and 
the present invention and protected by the folloWing claims. 
I claim: 
1. A method of treating choroidal neovascularization or 
Wet macular degeneration, comprising administering an 
effective amount of a CCR3-speci?c binding molecule to a 
patient having choroidal neovascularization or Wet macular 
degeneration Wherein the speci?c binding molecule is a small 
organic molecule. 
2. The method of claim 1 Wherein the CCR3-speci?c bind 
ing molecule is orally administered to the patient. 
3. The method of claim 1 Wherein the CCR3-speci?c bind 
ing molecule is intravenously administered to the patient. 
4. The method of claim 1 Wherein the CCR3-speci?c bind 
ing molecule is intraocularly injected into the patient. 
5. The method of claim 1 Wherein the CCR3-speci?c bind 
ing molecule is topically administered to the patient via eye 
drops. 
6. The method of claim 1 Wherein the CCR3-speci?c bind 
ing molecule is an organic molecule With a molecular Weight 
less than 2000. 
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7. The method of claim 1 wherein the CCR3-speci?c bind 
ing molecule is an organic molecule With a molecular Weight 
less than 1000. 
8. The method of claim 1 Wherein the CCR3-speci?c bind 
ing molecule is an organic molecule With a molecular Weight 
less than 500. 
9. The method of claim 1 Wherein the CCR3-speci?c bind 
ing molecule is (S)-methyl-2-naphthoylamino-3-(4-nitro 
phenyl)propionate. 
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